Precision oncology firm Guardant Health reports strong growth driven by rising adoption of its blood and tissue cancer tests.
Guardant Health (NASDAQ:GH) closed at $159.79 on August 04, 2026, reflecting a 258.35% gain over the past 52 weeks. The company’s shares rose 2.32% in the last month, outpacing broader market trends in the health care sector.
The precision oncology firm, which provides blood and tissue tests alongside data sets, has seen momentum in its cancer diagnostics business. Baron Health Care Fund cited Guardant Health as a top performer in Q2 2026, contributing to the fund’s 11.99% quarterly gain.
Baron Capital’s fund outperformed the Russell 3000 Health Care Index’s 10.48% gain but trailed the broader Russell 3000 Index’s 15.44% return. Strong stock selection in biotechnology and life sciences tools drove the fund’s performance.